Mitoxantrone hydrochloride is a Small Molecule owned by CSPC Pharmaceutical Group, and is involved in 42 clinical trials, of which 7 were completed, 21 are ongoing, and 14 are planned.

Mitoxantrone hydrochloride acts by inhibiting topoisomerase II. Topoisomerase II produces transient double-strand breaks in DNA and removes DNA supercoiling and tangles. Topoisomerase II is responsible for uncoiling and repairing damaged DNA. Mitoxantrone is a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes cross links and strand breaks. 

The revenue for Mitoxantrone hydrochloride is expected to reach a total of $1.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Mitoxantrone hydrochloride NPV Report.

Mitoxantrone hydrochloride is currently owned by CSPC Pharmaceutical Group.

Mitoxantrone hydrochloride Overview

Mitoxantrone hydrochloride is a anthracenedione antibiotic with antineoplastic activity. It is formulated as liposomal solution for intravenous route of administration. Mitoxantrone Hydrochloride is indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Mitoxantrone hydrochloride is under development for the treatment of recurrent/metastatic head and neck squamous cell carcinoma, relapsed or refractory multiple myeloma, HER-2 negative and positive advanced breast cancer, advanced solid tumor, advanced or metastatic urothelial cancer, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, soft tissue sarcoma, bone sarcoma, angioimmunoblastic T-cell lymphoma, large anaplastic T-cell lymphoma, epithelial ovarian cancer, nasopharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, fallopian tube carcinoma, acute myeloid leukemia (AML), advanced pancreatic cancer, primary peritoneal cancer, anaplastic large T-cell lymphoma, advanced hepatocellular carcinoma, metastatic breast cancer, natural killer cell lymphoma, T-cell lymphomas, peripheral T cell lymphoma, small cell lung cancer and peripheral T/NK cell non-Hodgkin lymphomas, gastric cancer, gastroesophageal junction cancer, colorectal cancer, lymphoma-associated hemophagocytic syndrome, lymphoblastic lymphoma, Burkitt's lymphoma, neuroblastoma. The drug is a liposomal formulation and administered by parenteral route and intravenous route of administration as an infusion. The drug acts by targeting type II topoisomerase. It was under development for cutaneous T-cell lymphoma, mantle cell lymphoma, anaplastic large-cell lymphoma, follicular lymphoma and small lymphocytic lymphoma.

It was also under development for the treatment of relapsing multiple sclerosis (RMS).

CSPC Pharmaceutical Group Overview

CSPC Pharmaceutical Group (CSPC) is a pharmaceutical company, which provides innovative, common generic and bulk drugs. The company manufactures, research and markets medicines and pharmaceutical related products. CSPC product portfolio includes capsules, tablets, injections, caffeine and antibiotics such as acarbose, penicillin sodium, cefazolin sodium and meropenem. The company offers its products for various diseases including ovarian cancer, breast cancer, hypertension and childhood acute lymphoblastic leukemia. Its drugs focus on major therapeutic areas such as neurology, diabetes, cardio-cerebrovascular, oncology and anti-infective. The company operates in the Americas, Europe and Asia. CSPC Pharma is headquartered in Shijiazhuang, Hebei, China.

The company reported revenues of (Renminbi) CNY27,866.9 million for the fiscal year ended December 2021 (FY2021), an increase of 11.7% over FY2020. In FY2021, the company’s operating margin was 24.5%, compared to an operating margin of 25.6% in FY2020. In FY2021, the company recorded a net margin of 20.1%, compared to a net margin of 20.7% in FY2020. The company reported revenues of CNY7,885.5 million for the third quarter ended September 2022, an increase of 1.9% over the previous quarter.

Quick View – Mitoxantrone hydrochloride

Report Segments
  • Innovator (NME)
Drug Name
  • Mitoxantrone hydrochloride
Administration Pathway
  • Intravenous
  • Parenteral
Therapeutic Areas
  • Central Nervous System
  • Hematological Disorders
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.